

# PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2026-02-25

## ZINZINO AB (PUBL.): YEAR-END REPORT 2025

### INCREASES DIVIDEND BY 50% TO SEK 6 AFTER HIGH GROWTH AND SIGNIFICANT IMPROVEMENT IN PROFITABILITY

Revenue for the fourth quarter of 2025 amounted to SEK 1,035.3 (713.5) million, corresponding to 45% (35%) growth compared with the same period last year. In local currencies, revenue for the fourth quarter increased by 52% compared with the corresponding period last year. EBITDA rose to SEK 175.2 (72.9) million after the EBITDA margin increased to 16.9% (10.2%). The improved EBITDA margin compared to the corresponding period last year was mainly due to stronger gross profit and increased synergies, primarily related to the acquisition of Zurvita. During the quarter, Zinzino acquired 35% of the shares in Xion International Group with the aim of producing algae using bioreactors, thereby securing a sustainable future supply of omega-3 for the company's main product, BalanceOil. In addition, the assets of the direct sales company Sanki were acquired to increase distribution power in North and South America, and the Gut Health Test was launched.

For the full year 2025, total revenue amounted to SEK 3,337.5 (2,207.8) million, corresponding to 51% (25%) growth compared with the previous year. EBITDA amounted to SEK 443.4 (250.7) million and the EBITDA margin was 13.3% (11.4%). Following the positive results for the past year, the Board of Directors will propose a dividend of SEK 6.00 (4.00) per share for the 2025 financial year at the Annual General Meeting on June 2, 2026.

#### OCTOBER – DECEMBER

- Total revenue amounted to SEK 1,035.3 (713.5) million, corresponding to growth of 45% (35%)
- Gross profit amounted to SEK 370.3 (218.4) million and the gross profit margin was 35.8% (30.6%)
- EBITDA amounted to SEK 175.2 (72.9) million and the EBITDA margin amounted to 16.9% (10.2%)
- Net profit amounted to SEK 123.7 (43.2) million
- Net profit per share after tax before dilution amounted to SEK 3.41 (1.25)
- Cash flow from operating activities amounted to SEK 271.5 (174.7) million

#### JANUARY-DECEMBER

- Total revenue amounted to SEK 3,337.5 (2,207.8) million, corresponding to growth of 51% (25%)
- Gross profit amounted to SEK 1,119.1 (732.5) million and the gross profit margin amounted to 33.5% (33.2%)
- EBITDA amounted to SEK 443.4 (250.7) million and the EBITDA margin was 13.3% (11.4%)
- Net profit amounted to SEK 324.5 (169.3) million.
- Net profit per share after tax before dilution amounted to SEK 9.09 (4.95)
- Cash flow from operating activities amounted to SEK 541.8 (303.1) million
- Cash and cash equivalents amounted to SEK 771.0 (463.1) million on the balance sheet date
- Zinzino's Board of Directors proposes a dividend to shareholders of SEK 6.00 (4.00) SEK per share for the 2025 financial year, corresponding to a total of SEK 217.9 (143.1) million before dilution through the registration of directed issues linked to completed acquisitions and option redemptions in 2026 until the Annual General Meeting

#### EVENTS AFTER THE REPORTING DATE

- Acquisition of It Works! for increased distribution power in North America and Europe

#### Link to the report:

<https://www.zinzino.com/site/SE/sv-SE/om-oss/investerare/>

**For more information, please contact:**

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, [dag@zinzino.com](mailto:dag@zinzino.com)

Fredrik Nielsen CFO Zinzino +46 707 900 174, [fredrik.nielsen@zinzino.com](mailto:fredrik.nielsen@zinzino.com)

**Images for free publication:**

[marketing@zinzino.com](mailto:marketing@zinzino.com)

**Certified Adviser:** Tapper Partners AB

Zinzino AB (publ.) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 08:00 CET on 25 February 2026.

---

Zinzino is a global health tech company from Scandinavia, pioneering a new standard in personal health through advanced home health tests and scientifically proven nutritional supplements. Listed on the Nasdaq First North Premier Growth Market, the company's test-based, personalized nutrition strategy empowers individuals to take charge of their long-term health with science-based insights and targeted solutions. Its third-party validated products are available through direct sales distributors in more than 100 markets worldwide. Zinzino's headquarters are located in Gothenburg, Sweden, with additional offices across Europe, Asia, and Australia.